Free Daily Podcast Summary
Psychopharmacology and Psychiatry Updates: Daily Summaries Delivered
by Psychopharmacology Institute
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago12 min
EMERGENT-5: Cobenfy and Treatment Durability
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 85 Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?
- 1 weeks ago14 min
Antipsychotics and Weight Gain
In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know Antipsychotic-Induced Weight Gain: Prevention and Management
- 1 weeks ago12 min
EPA vs. DHA: Fish Oil and Treatment-Resistant Depression
In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms. Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CMEs: Quick Take Vol. 84 Eicosapentaenoic Acid: Effective as Adjunctive for TRD?
- 2 weeks ago10 min
AUD Medications and Hepatic Safety
In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status
- 3 weeks ago15 min
GLP-1 Agonists in Serious Mental Illness: Current Evidence
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done? Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?
- 3 weeks ago17 min
Gabapentin, Topiramate & Baclofen in AUD
In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder
- Aug 19, 202617 min
Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good
In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 Benzodiazepine Tapering: Key Takeaways From New Guidelines
- Aug 14, 202616 min
Disulfiram Unpacked: Efficacy, Risks, and Liver Safety
In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations
About Psychopharmacology and Psychiatry Updates
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Psychopharmacology and Psychiatry Updates in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Psychopharmacology and Psychiatry Updates daily summary?
It's a free AI-powered email that summarizes new episodes of Psychopharmacology and Psychiatry Updates as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Psychopharmacology and Psychiatry Updates podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Psychopharmacology and Psychiatry Updates product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Psychopharmacology Institute.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Psychopharmacology and Psychiatry Updates release new episodes?
Psychopharmacology and Psychiatry Updates publishes 2x weekly. Our AI generates a summary within hours of each new episode.
What topics does Psychopharmacology and Psychiatry Updates cover?
Psychopharmacology and Psychiatry Updates covers topics including Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Psychopharmacology and Psychiatry Updates summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.